Blood
Articles in this Issue
Dissecting complement pathway activation after allogeneic hematopoietic cell transplant: Results of a monocentric longitudinal monitoring program.
Abstract Systemic complement activation is a well-established pathophysiological mechanism involved in endothelial complications, particular...
Discovery of bispecific T-cell engagers targeting the non-mutated regions of mutant calreticulin for the treatment of myeloproliferative neoplasms
Abstract Introduction Calreticulin (CALR) is a chaperone protein found in the endoplasmic reticulum (ER). A +1 frameshift mutation in exon 9...
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
Abstract Introduction: Older adults (OAs) with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients (pts). NA...
Real-world outcomes of HIV-associated lymphomas: A retrospective study at a single tertiary center in Saudi Arabia
Abstract Background Lymphoma is a hematologic malignancy that occurs at a higher rate among individuals infected with the human immunodefici...
Triglycerides, but not bilirubin or hemoglobin, can interfere with the modified ham (mHam) functional complement assay
Abstract Complement-mediated thrombotic microangiopathy (CM-TMA)/atypical hemolytic uremic syndrome (aHUS) is a rare, potentially lethal TMA...
Sex disparities in sickle cell disease admissions in United States: A national in-patient sample study from 2016-2022
Abstract Background: Sickle cell disease (SCD) is a chronic, inherited hemoglobinopathy associated with significant morbidity and mortality....
Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.
Abstract BACKGROUND While Chimeric Antigen Receptor T cell (CAR-T) therapies and bispecific antibodies (bAbs) can lead to remarkable respons...
Sustained donor engraftment and clinical remission after hematopoietic cell transplantation for vexas syndrome, but with observed toxicities: Results from a prospective phase II clinical Trial
Abstract VEXAS is a recently described autoinflammatory disorder with bone marrow failure, caused by somatic mutations in UBA1. Disease is l...
Community health worker training for sickle cell disease education in the consortium for newborn screening in Africa
Abstract Sub-Saharan Africa bears more than 75% of the global burden of sickle cell disease (SCD), where limited newborn screening, diagnost...
Inotuzumab ozogamacin in refractory or 1st or greater relapse of pediatric B-ALL as bridge to cure: A single center experience
Abstract Introduction: B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Cooperative grou...
Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial
Abstract Introduction: Chronic lymphocytic leukemia (CLL) is marked by impaired T cell responses that limit the efficacy of immunotherapies....
Outcomes and cause-specific mortality of AML in adults from Chile
Abstract Background: Real-world long-term outcomes for patients with AML in Latin America are not well described. In this analysis we presen...
Trends in sepsis-related mortality among patients with Acute Myeloid Leukemia: A 24-year nationwide analysis
Abstract Background: Sepsis is a frequent and life-threatening complication in acute myeloid leukemia (AML), driven by disease-related immun...
Efficacy and safety of rituximab, high-dose methotrexate, and thiotepa (R-MT) as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma
Abstract Background and Objectives Primary central nervous system lymphoma (PCNSL) is a rare, centrally localized lymphoma with a poor progn...
Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.
Abstract Background: B cell maturation antigen (BCMA) targeted Chimeric antigen receptor (CAR) T cell therapy has emerge...
AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies
Abstract Despite advances in the treatment of B-cell non-Hodgkin lymphomas (B-NHL) and B-cell acute lymphoblastic leukemia (B-ALL), disease...
Impact of pre-transplant chemotherapy cycles on allogeneic hematopoietic cell transplant outcomes in pediatric acute myeloid leukemia
Abstract Introduction Allogeneic hematopoietic cell transplant (HCT) improves the outcomes of pediatric patients with high-risk acute myeloi...
Clinical and molecular predictors of interferon-α response in erdheim-chester disease and myeloproliferative neoplasm.
Abstract Background: Erdheim–Chester disease (ECD) is a rare clonal histiocytosis driven by MAPK pathway somatic mutations, causing multi-org...
Gastrointestinal and hepatobiliary toxicities associated with bispecific antibody therapy in hematologic malignancies: A retrospective single-center study.
Abstract Background: Bispecific antibody (bsAb) therapies have revolutionized treatment of hematologic malignancies; how...
Real-world outcomes of glofitamab therapy in CAR-T naive patients with relapsed/refractory B-cell lymphoma
Abstract Background The bispecific antibody (BsAb) glofitamab (G) has demonstrated high efficacy and acceptable feasibility in patients with...
A preliminary study on the roles and mechanisms of IL-17A monoclonal antibody in chronic graft-versus-host disease
Abstract Objective: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for hematological diseases, but...
The receptor tyrosine kinase EphA2 promotes thrombogenesis and impairs thrombus resolution in deep vein thrombosis
Abstract Background: Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), significantly contri...
Association of CD34+ cell dose on outcome after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT) for adults with Acute Myeloid Leukemia (AML) in measurable residual disease (MRD)-negative remission
Abstract BACKGROUND: Reduced-intensity conditioning (RIC) has expanded access of allogeneic hematopoietic cell transplan...
Chemo-free regimen based on venetoclax and azacytidine as induction therapy for adults with newly-diagnosed mixed phenotype acute leukemia
Abstract Introduction Mixed phenotype acute leukemia (MPAL) is a rare type of leukemia with a poor prognosis and lack of standard treatment....
Unpredictability of caregiver gaps in multiple myeloma: Results from a survey of >1000 patients
Abstract Background: Social determinants of health (SDOH) are critical drivers of cancer care access and outcomes. In mu...